BCM
RIGL icon

BlueCrest Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

BlueCrest Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,759
Closed -$249K – 1327
2018
Q3 		$249K Buy
+7,759
New +$233K 0.01% 1140
2017
Q4 		– Sell
-1,055
Closed -$27K – 1053
2017
Q3 		$27K Buy
+1,055
New +$25.7K ﹤0.01% 822

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlueCrest Capital Management's RIGL Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2018, closing a stake of 7,759 shares — an estimated $249K sold.

BlueCrest Capital Management first reported a position in RIGL in Q3 2017 and held it in 2 quarters. The position peaked at $249K in Q3 2018. 133 funds tracked by Wall St. Rank hold RIGL as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 7,759 Rigel Pharmaceuticals shares in Q4 2018, an estimated $249K.
  • BlueCrest Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Rigel Pharmaceuticals position peaked at $249K in Q3 2018.
  • 133 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.